Literature DB >> 16225826

MECP2 abnormality phenotypes: clinicopathologic area with broad variability.

Anna Erlandson1, Bengt Hagberg.   

Abstract

Rett syndrome is a neurodevelopmental disorder that occurs worldwide and predominantly affects girls. The MECP2 gene has been put forward as the underlying gene. Interestingly, other clinical presentations in addition to Rett syndrome have been reported to be the results of deviations in MECP2. This prompted us to outline a working hypothesis of how these diverse phenotypes are connected. Our aim was to summarize the clinical picture of deviations in MECP2 at this moment to obtain a comprehensive overview. Thus, we have attempted to create a gradient, starting at the left with the most severely affected MECP2-deviant subgroups, represented by boys who are diseased in the intrauterine phase or as neonates, and at the right, the most mildly affected subgroup, female asymptomatic carriers. In the center, with dominant numbers, we have placed classic Rett syndrome presentations, together with the late-onset Rett syndrome variant and preserved speech variant. In conclusion, we feel that it is important to emphasize that Rett syndrome is a strictly clinical diagnosis that is not identical to the far broader concept of MECP2 deviations.

Entities:  

Mesh:

Year:  2005        PMID: 16225826     DOI: 10.1177/08830738050200090501

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  9 in total

Review 1.  Emerging pharmacotherapies for neurodevelopmental disorders.

Authors:  Daniel Z Wetmore; Craig C Garner
Journal:  J Dev Behav Pediatr       Date:  2010-09       Impact factor: 2.225

2.  Early motor phenotype detection in a female mouse model of Rett syndrome is improved by cross-fostering.

Authors:  Annie Vogel Ciernia; Michael C Pride; Blythe Durbin-Johnson; Adriana Noronha; Alene Chang; Dag H Yasui; Jacqueline N Crawley; Janine M LaSalle
Journal:  Hum Mol Genet       Date:  2017-05-15       Impact factor: 6.150

Review 3.  A review of Rett syndrome (RTT) with induced pluripotent stem cells.

Authors:  Vellingiri Balachandar; Venkatesan Dhivya; Mohan Gomathi; Subramaniam Mohanadevi; Balasubramanian Venkatesh; Bharathi Geetha
Journal:  Stem Cell Investig       Date:  2016-09-28

Review 4.  Clinical and biological progress over 50 years in Rett syndrome.

Authors:  Helen Leonard; Stuart Cobb; Jenny Downs
Journal:  Nat Rev Neurol       Date:  2016-12-09       Impact factor: 42.937

5.  A novel hypomorphic MECP2 point mutation is associated with a neuropsychiatric phenotype.

Authors:  Abidemi A Adegbola; Michael L Gonzales; Andrew Chess; Janine M LaSalle; Gerald F Cox
Journal:  Hum Genet       Date:  2008-11-07       Impact factor: 4.132

6.  Pharmacology and genetics of autism: implications for diagnosis and treatment.

Authors:  Zoran Brkanac; Wendy H Raskind; Bryan H King
Journal:  Per Med       Date:  2008-11       Impact factor: 2.512

7.  Clinical genetics evaluation in identifying the etiology of autism spectrum disorders.

Authors:  G Bradley Schaefer; Nancy J Mendelsohn
Journal:  Genet Med       Date:  2008-04       Impact factor: 8.822

8.  Clinical genetic testing for patients with autism spectrum disorders.

Authors:  Yiping Shen; Kira A Dies; Ingrid A Holm; Carolyn Bridgemohan; Magdi M Sobeih; Elizabeth B Caronna; Karen J Miller; Jean A Frazier; Iris Silverstein; Jonathan Picker; Laura Weissman; Peter Raffalli; Shafali Jeste; Laurie A Demmer; Heather K Peters; Stephanie J Brewster; Sara J Kowalczyk; Beth Rosen-Sheidley; Caroline McGowan; Andrew W Duda; Sharyn A Lincoln; Kathryn R Lowe; Alison Schonwald; Michael Robbins; Fuki Hisama; Robert Wolff; Ronald Becker; Ramzi Nasir; David K Urion; Jeff M Milunsky; Leonard Rappaport; James F Gusella; Christopher A Walsh; Bai-Lin Wu; David T Miller
Journal:  Pediatrics       Date:  2010-03-15       Impact factor: 7.124

9.  Protective role of mirtazapine in adult female Mecp2+/- mice and patients with Rett syndrome.

Authors:  Javier Flores Gutiérrez; Claudio De Felice; Giulia Natali; Silvia Leoncini; Cinzia Signorini; Joussef Hayek; Enrico Tongiorgi
Journal:  J Neurodev Disord       Date:  2020-09-28       Impact factor: 4.025

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.